Accera And University Of Miami Announce Collaboration To Study Axona® For Cognitive Impairment In Patients With Multiple Sclerosis
"We are very excited about this project," said Holger Kunze, CEO at Accera. "This collaboration fits well with Accera's mission to help patients with neurological disorders by addressing metabolic deficiencies common in these disease states."
About Axona™Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. For more information about Axona, please visit www.about-axona.com.
About Medical FoodsA medical food is a product intended for the clinical dietary management of a disease or condition for which distinctive nutritional requirements are established scientifically. Medical foods are intended to be used under physician supervision, must be composed of approved food ingredients or generally recognized as safe and must comply with FDA regulations and guidelines that pertain to labeling, product claims and manufacturing.
About Accera, Inc.Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US. Accera is engaged in the research, development and commercialization of other clinical applications for Axona and AC-1204 in acute and chronic neurodegenerative diseases. For more information about Accera, please visit www.accerapharma.com.About University of Miami Founded in 1952 as Florida's first accredited medical school, the University of Miami Leonard M. Miller School of Medicine provides medical staff for the nationally renowned University of Miami/Jackson Memorial Medical Center and University of Miami Hospital. University of Miami Hospital is the flagship facility of UHealth, which also includes two additional University-owned hospitals: Sylvester Comprehensive Cancer Center and Anne Bates Leach Eye Hospital, home to the top-ranked Bascom Palmer Eye Institute. Our affiliated hospitals on the medical campus include Jackson Memorial Hospital, Holtz Children's Hospital, and the Miami VA Medical Center. http://www.med.miami.edu About multiple sclerosisMultiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common. About Fast Forward, LLC Fast Forward, LLC, established by the National Multiple Sclerosis Society as part of a comprehensive approach to MS research and treatment, focuses on speeding promising research discoveries towards commercial drug development. Fast Forward accelerates the development of treatments for MS by connecting university-based MS research with private-sector drug development and by funding small biotechnology/pharmaceutical companies to develop innovative new MS therapies and repurpose FDA-approved drugs as new treatments for MS. For more information, please visit www.fastforward.org. About the National Multiple Sclerosis SocietyThe National MS Society addresses the challenges of each person affected by MS. To fulfill this mission, the Society funds cutting-edge research, drives change through advocacy, facilitates professional education, collaborates with MS organizations around the world, and provides programs and services designed to help people with MS and their families move forward with their lives. In 2012 alone, the Society invested $43 million to support 350 research projects around the world while providing programs and services that assisted more than one million people. The Society is dedicated to achieving a world free of MS. Join the movement at www.nationalMSsociety.org. For media:Tiberend Strategic Advisors, Inc. Andrew Mielach and Claire Sojda firstname.lastname@example.org; 212-375-2694 email@example.com; 212-375-2686 SOURCE Accera, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV